Table 2

Comparison of the median survival time of patients with or without portal vein thrombosis and/or distant metastasis
Groups n Mean (95% Confidence Interval) Pvalue
HCC without portal vein thrombosis/metastasis TACE 22 15.94 (11.87–20.01) 0.027
TACE + Sorafenib 25 29.09 (22.76–35.41)
HCC with portal vein thrombosis/metastasis TACE 23 12.00 (9.96–16.02) 0.041
TACE + Sorafenib 20 27.20 (19.07–35.32)

Qu et al.

Qu et al. BMC Cancer 2012 12:263   doi:10.1186/1471-2407-12-263

Open Data